JP2017532378A5 - - Google Patents

Download PDF

Info

Publication number
JP2017532378A5
JP2017532378A5 JP2017538918A JP2017538918A JP2017532378A5 JP 2017532378 A5 JP2017532378 A5 JP 2017532378A5 JP 2017538918 A JP2017538918 A JP 2017538918A JP 2017538918 A JP2017538918 A JP 2017538918A JP 2017532378 A5 JP2017532378 A5 JP 2017532378A5
Authority
JP
Japan
Prior art keywords
phospholipid
polymer
liposome composition
aromatic
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017538918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532378A (ja
JP6505235B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/054732 external-priority patent/WO2016057812A1/en
Publication of JP2017532378A publication Critical patent/JP2017532378A/ja
Publication of JP2017532378A5 publication Critical patent/JP2017532378A5/ja
Application granted granted Critical
Publication of JP6505235B2 publication Critical patent/JP6505235B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017538918A 2014-10-08 2015-10-08 リポソームを用いるアミロイド斑のｍｒｉイメージング Active JP6505235B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462061514P 2014-10-08 2014-10-08
US62/061,514 2014-10-08
US201562111057P 2015-02-02 2015-02-02
US62/111,057 2015-02-02
PCT/US2015/054732 WO2016057812A1 (en) 2014-10-08 2015-10-08 Mri imaging of amyloid plaque using liposomes

Publications (3)

Publication Number Publication Date
JP2017532378A JP2017532378A (ja) 2017-11-02
JP2017532378A5 true JP2017532378A5 (enExample) 2018-11-22
JP6505235B2 JP6505235B2 (ja) 2019-04-24

Family

ID=55653789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017538918A Active JP6505235B2 (ja) 2014-10-08 2015-10-08 リポソームを用いるアミロイド斑のｍｒｉイメージング

Country Status (10)

Country Link
US (4) US9744251B2 (enExample)
EP (3) EP3204051B1 (enExample)
JP (1) JP6505235B2 (enExample)
KR (1) KR102409017B1 (enExample)
CN (1) CN107106708B (enExample)
AU (2) AU2015330824A1 (enExample)
CA (1) CA2963941C (enExample)
ES (2) ES2743704T3 (enExample)
MX (1) MX371295B (enExample)
WO (1) WO2016057812A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3366313A1 (en) 2011-04-06 2018-08-29 Board Of Regents Of the University Of Texas System Lipid-based nanoparticles
JP6130401B2 (ja) 2012-01-20 2017-05-17 アンナプラガダ，アナンス 医学画像を客観的に特徴付けるための方法および組成物
CN107106708B (zh) 2014-10-08 2021-06-18 德克萨斯州儿童医院 使用脂质体进行的淀粉样蛋白斑mri成像
MX386900B (es) 2016-07-22 2025-03-19 Ac Immune S A Star Compuestos para formacion de imagenes de agregados de proteinas tau.
WO2018015546A1 (en) 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
US11052162B2 (en) 2016-09-16 2021-07-06 Texas Children's Hospital Liposomal gadolinium (GD) contrast agent “NMRX” for T1-MRI
CN110022859B (zh) * 2016-11-30 2022-10-28 德克萨斯州儿童医院 具有独特的mr特征用于脂质体19f mri探针的亲水性氟化分子
EP3743423A1 (en) 2018-01-24 2020-12-02 AC Immune SA Gamma-carboline compounds for the detection of tau aggregates
EP3743426A1 (en) 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates
US20210008204A1 (en) * 2018-03-29 2021-01-14 Microvascular Therapeutics LLC Compositions and methods of detecting and treating alzheimer's disease
KR20210020072A (ko) 2018-06-08 2021-02-23 에이씨 이뮨 에스.에이. 진단을 위한 신규한 화합물
EP3914230A4 (en) * 2019-01-24 2023-06-07 Alzeca Biosciences, Llc <SMALLCAPS/>? ? ?FUNCTIONALIZED LIPOSOMES FOR IMAGE MISFOLDED PROTEINS
WO2021007232A1 (en) * 2019-07-08 2021-01-14 Alzeca Biosciences, LLC Targeting ligands for tau pathology
US11614451B2 (en) 2019-07-08 2023-03-28 Alzeca Biosciences, LLC Targeting ligands for tau pathology
CN115916263B (zh) * 2020-01-29 2025-10-03 德克萨斯儿童医院 用于淀粉样蛋白沉积mri的靶向对比剂
US11779664B2 (en) 2020-02-12 2023-10-10 Texas Children's Hospital Targeted contrast agents for MRI of alpha-synuclein deposition
CN115279424A (zh) * 2020-02-12 2022-11-01 德克萨斯儿童医院 用于α-突触核蛋白沉积MRI的靶向对比剂
CN115970009A (zh) * 2023-02-08 2023-04-18 丽水市中心医院 Vhpk多肽修饰的荧光纳米脂质体给药系统、其制备方法及应用
CN116869938A (zh) * 2023-07-26 2023-10-13 安徽医科大学 一种1,2,4-噁二唑-吡啶脂质体及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204085A (en) 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
ZA952485B (en) 1994-03-28 1995-12-15 Nycomed Imaging As Liposomes
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
DE60017787T2 (de) 1999-11-30 2006-01-05 ARIZONA BOARD OF REGENTS, on behalf of THE UNIVERSITY OF ARIZONA, Tucson Strahlung-sensitive liposomen
AU2002211517A1 (en) 2000-10-04 2002-04-15 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
WO2002094191A2 (en) 2001-05-23 2002-11-28 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
US7138136B2 (en) 2002-03-05 2006-11-21 Cleveland State University Agglomerated particles for aerosol drug delivery
US7605182B2 (en) 2003-05-01 2009-10-20 Aposense Ltd. Compounds that selectively bind to membranes of apoptotic cells
US7208174B2 (en) 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
ATE493152T1 (de) 2004-09-23 2011-01-15 Guerbet Sa Liposomale kontrastmittel für die cest-bildgebung
WO2007119108A2 (en) 2005-10-13 2007-10-25 Waratah Pharmaceuticals Inc. Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
US20070160658A1 (en) 2005-10-20 2007-07-12 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
US20090123047A1 (en) 2007-03-21 2009-05-14 Yfantis Spyros A Method and system for characterizing prostate images
EP1982733A1 (en) 2007-04-17 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Use of a contrast agent for magnetic resonance imaging of endoleaks
US7858803B2 (en) 2007-04-27 2010-12-28 The General Hospital Corporation Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders
US20110311457A1 (en) 2007-07-26 2011-12-22 Nanoscan Imaging, Llc Methods for imaging vascular inflammation using improved nanoparticle contrast agents
JP2011506325A (ja) 2007-12-05 2011-03-03 マーバル バイオサイエンシーズ インコーポレイテッド ナノスケールのコントラスト剤及びその使用方法
JP5647899B2 (ja) 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
ITMI20081052A1 (it) 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
WO2009152445A1 (en) 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
WO2010017094A2 (en) 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US20120003159A1 (en) 2009-03-19 2012-01-05 Board Of Regents Of The University Of Texas System Compositions and methods for enhancing contrast in imaging
EP2501696B1 (en) 2009-10-15 2016-12-28 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
EP2582674B1 (en) 2010-06-16 2014-10-01 Cymabay Therapeutics, Inc. Gpr120 receptor agonists and uses thereof
MX345504B (es) 2011-03-02 2017-02-02 Sensulin Llc Composiciones de vesicula.
EP3366313A1 (en) 2011-04-06 2018-08-29 Board Of Regents Of the University Of Texas System Lipid-based nanoparticles
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
JP6130401B2 (ja) 2012-01-20 2017-05-17 アンナプラガダ，アナンス 医学画像を客観的に特徴付けるための方法および組成物
WO2013164763A2 (en) * 2012-04-30 2013-11-07 Innovative Health Diagnostics A biological complex specific for alzheimer's disease detection in vitro and use thereof
AU2014240042C1 (en) * 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
CN107106708B (zh) 2014-10-08 2021-06-18 德克萨斯州儿童医院 使用脂质体进行的淀粉样蛋白斑mri成像

Similar Documents

Publication Publication Date Title
JP2017532378A5 (enExample)
Wang et al. Manganese-based contrast agents for magnetic resonance imaging of liver tumors: Structure–activity relationships and lead candidate evaluation
TW319763B (enExample)
US20200179540A1 (en) Mri imaging of amyloid plaque using liposomes
JP6722663B2 (ja) マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法
US8647604B2 (en) Lanthanide rich nanoparticles, and their investigative uses in MRI and related technologies
US20180303960A1 (en) Combination Formulation
JP6212032B2 (ja) 脂質ベースのナノ粒子
Tanifum et al. A novel liposomal nanoparticle for the imaging of amyloid plaque by magnetic resonance imaging
RU2012124266A (ru) Хелаты марганца и их применение в качестве контрастных агентов в магнитно-резонансной визуализации (mpb)
JP2014523854A5 (enExample)
JP7114074B2 (ja) 画像化のためのニトロキシドを含むアミロイド結合剤およびその治療的使用
CN102802672B (zh) 髓鞘碱性蛋白的成像
JP7663663B2 (ja) アミロイド沈着のｍｒｉのための標的造影剤
Urbanovsky et al. Lanthanide complexes of DO3A–(Dibenzylamino) methylphosphinate: effect of Protonation of the Dibenzylamino Group on the water-exchange rate and the binding of human serum albumin
Li et al. Protein MRI contrast agents as an effective approach for precision molecular imaging
JP2018523657A5 (enExample)
JP4786112B2 (ja) 金属イオンキレート化錯体と共役させた胆汁酸誘導体の微小血管の診断評価のための使用
Granato et al. Synthesis and relaxometric characterization of new Poly [N, N‐bis (3‐aminopropyl) glycine](PAPGly) Dendrons Gd‐based contrast agents and their in vivo study by using the dynamic contrast‐enhanced MRI technique at low field (1 T)
WO2007128567A1 (de) Verwendung von perfluoralkylhaltigen metallkomplexen als kontrastmittel zur diagnose der alzheimer krankheit
Chang et al. Dynamic contrast-enhanced magnetic resonance imaging evaluation of VX2 carcinoma in a rabbit model: comparison of 1.0-M gadobutrol and 0.5-M gadopentetate dimeglumine
Petiet et al. Improvement of microscopic MR imaging of amyloid plaques with targeting and non-targeting contrast agents
Djanashvili et al. Responsive nanozeolites: Smart porosity and surface tailoring for multimodal imaging and therapy of cancer
WO2022040649A1 (en) Diffusivity contrast agents for medical imaging
Fransen et al. r1 and r2 Relaxivities of Dendrons Based on a OEG‐DTPA Architecture: Effect of Gd3+ Placement and Dendron Functionalization